<SEC-DOCUMENT>0001564590-21-026582.txt : 20210511
<SEC-HEADER>0001564590-21-026582.hdr.sgml : 20210511
<ACCEPTANCE-DATETIME>20210511163034
ACCESSION NUMBER:		0001564590-21-026582
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210511
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210511
DATE AS OF CHANGE:		20210511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		21911733

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-8k_20210511.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20210511.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:justify;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="color:#000000;font-size:12pt;"> </font><font style="color:#000000;">May 11, 2021</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10170 Church Ranch Way, Suite 100, Westminster, CO</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">80021</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (720) 940-2200</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:12pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:86.67%;">
<tr>
<td style="width:25.83%;"></td>
<td style="width:20%;"></td>
<td style="width:40.83%;"></td>
</tr>
<tr style="height:12.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:16.6pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABIO</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Capital Market</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:justify;margin-top:4pt;border-top:Solid 0.75pt #000000;padding-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;2 &#8212; Financial Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.02.</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations and Financial Condition.</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 11, 2021, ARCA biopharma, Inc., or ARCA, issued a press release reporting financial results for the quarter ended March&#160;31,&#160;2021.&nbsp;&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The press release is attached hereto as Exhibit&#160;99.1, which is furnished under Item 2.02 of this report and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9 &#8212; Financial Statements and Exhibits </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:78.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex991_6.htm"><font style="text-decoration:underline;">Press Release titled &#8220;ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update&#8221; dated May 11, 2021</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 11, 2021</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ C. Jeffrey Dekker</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Jeffrey Dekker</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abio-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lggkl0umxl000001.jpg" title="" alt="" style="width:203px;height:69px;"></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:48.89%;"><br />&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARCA <font style="text-transform:none;">biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">------------------------------------------------------------------------------------------------------------ </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID&#8209;19 anticipated in the third quarter of 2021</font></p></td></tr></table></div>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Westminster, CO, May 11, 2021<font style="font-style:normal;"> &#8211; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2021 financial results and provided a corporate update.</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Michael Bristow, ARCA&#8217;s President and Chief Executive Officer, commented, &#8220;We are continuing to advance the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19, actively enrolling patients at 7 clinical trial sites in the United States.&nbsp;&nbsp;We look forward to sharing the trial results early in the third quarter of this year. We believe rNAPc2&#8217;s combination of anticoagulant, anti-inflammatory and antiviral properties, give it the potential to be effective in addressing the impact of COVID-19 from multiple pathways. As a therapeutic aimed at a host response to a disease syndrome, we believe rNAPc2 has therapeutic potential for future viral outbreaks beyond the current pandemic, even after safe and effective vaccines for SARS-CoV-2 are successfully deployed.&#8221; </p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pipeline Update</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">rNAPc2 (AB201)</font><font style="font-weight:normal;"> &#8211; a small recombinant protein being developed as a potential treatment for RNA virus associated disease, initially focusing on COVID-19.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19 initiated in December 2020.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Currently enrolling patients in ASPEN-COVID-19 at 7 clinical trial sites in the United States.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 2b topline data anticipated early in the third quarter of 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">U.S. Food and Drug Administration (FDA) designated the investigation of rNAPc2 as a potential treatment for COVID-19 as a Fast Track development program. </font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Gencaro</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="font-weight:normal;"> (</font><font style="font-weight:normal;">bucindolol</font><font style="font-weight:normal;"> hydrochloride) </font><font style="font-weight:normal;">- a</font><font style="font-weight:normal;"> pharmacologically unique beta-blocker and mild vasodilator being developed </font><font style="font-weight:normal;">as a</font><font style="font-weight:normal;"> potential</font><font style="font-weight:normal;"> genetically-targeted</font><font style="font-weight:normal;"> treatment </font><font style="font-weight:normal;">for </font><font style="font-weight:normal;">atrial fibrillation (AF) in patients with heart failure (HF</font><font style="font-weight:normal;">)</font><font style="font-weight:normal;">.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk66342858"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In February 2021, ARCA was issued a new patent by the </font><font style="text-decoration:underline;color:#000000;">United States Patent and Trademark Office</font><font style="color:#000000;"> (USPTO) for use of Gencaro in treating AF in patients with HF.  The Company believes this patent would provide effective patent coverage in the United States into 2039.&nbsp;&nbsp;ARCA has filed similar patent applications in other countries.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:16pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Company continues to evaluate the potential timing for initiation of PRECISION-AF relative to the COVID-19 pandemic and the ability to recruit patients for a cardiovascular clinical trial, and based on an improving clinical trial ecosystem, has begun organizing necessary trial logistics.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First Quarter 2021 Summary Financial Results<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents <font style="font-weight:normal;">were $66.9 million as of March 31, 2021, compared to $49.1&#160;million as of December 31, 2020.  ARCA believes that its current cash and cash equivalents will be sufficient to fund its operations through 2022. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and development (R&amp;D) expenses<font style="font-weight:normal;"> were $2.9 million for the quarter ended March 31, 2021, compared to $0.4 million for the corresponding period in 2020. The $2.5 million increase in R&amp;D expenses in the first quarter was primarily related to the initiation of the rNAPc2 clinical trial in the second half of 2020.&nbsp;&nbsp;R&amp;D expenses in 2021 are expected to be higher than 2020, as the Company continues the rNAPc2 Phase 2b clinical trial.</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General and administrative (G&amp;A) expenses<font style="font-weight:normal;"> were $1.2 million for the quarter ended March 31, 2021, compared to $1.0 million for the corresponding period in 2020. The $0.3 million increase in G&amp;A expenses was primarily a result of higher personnel costs in 2021.&nbsp;&nbsp;G&amp;A expenses in 2021 are expected to be consistent with those in 2020 as the Company maintains administrative activities to support its ongoing operations. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses<font style="font-weight:normal;"> for the quarter ended March 31, 2021 were $4.1 million compared to $1.3 million for the first quarter of 2020. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net loss<font style="font-weight:normal;"> for the quarter ended March 31, 2021 was $4.1 million, or $0.33 per basic and diluted share, compared to $1.3 million, or $0.83 per basic and diluted share for the first quarter of 2020.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About ARCA biopharma</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2 clinical testing. ARCA is also developing Gencaro<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit <font style="text-decoration:underline;">www.arcabio.com</font> or follow the Company on <font style="text-decoration:underline;">LinkedIn</font>. </p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Safe Harbor Statement</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential future development plans for rNAPc2 and Gencaro, the expected features and characteristics of rNAPc2 and Gencaro, including the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#8217;s potential to treat atrial fibrillation, rNAPc2&#8217;s potential to treat COVID-19, future treatment options for patients with COVID-19 or AF, the potential for Gencaro to be the first genetically targeted AF prevention treatment and the ability of ARCA&#8217;s financial resources to support its operations through 2022<font style="font-size:11.5pt;">. </font>Such statements are based on management's current expectations and involve risks and uncertainties.&nbsp;&nbsp;Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA&#8217;s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of rNAPc2 or Gencaro or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA&#8217;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.&nbsp;&nbsp;These and other factors are identified and described in more detail in ARCA&#8217;s filings with the Securities and Exchange Commission, including without limitation ARCA&#8217;s annual report on Form 10-K for the year ended December&#160;31,&#160;2020, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investor &amp; Media Contact:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derek Cole</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720.940.2163</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">derek.cole@arcabio.com</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Tables follow)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE SHEET DATA </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.17%;">
<tr>
<td style="width:49.33%;"></td>
<td style="width:22.5%;"></td>
<td style="width:23.33%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">March 31, 2021</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">December 31, 2020</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $66,933</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$49,071</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Working capital</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $65,850</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$46,469</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-5.25pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $69,183</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$50,429</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $65,909</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$46,521</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share</p>
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,876</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,102</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,320</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,356,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,594,070</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-align:left;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g5lggkl0umxl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lggkl0umxl000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "> =$# 2(  A$! Q$!_\0
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MI_X* >/5\*^#=1U>RFU HT>C^#8#8B!00ID>Y!,R1Y9=[23",9&<"O:?A/\
M\&\WC_XJ,=>^+/Q)M](U;4#'<36]K&^LWK[AEUGN)'15E4\93SE)R0Q'6/:-
M[(OV=MV?I)?_ +;'P;TJ;R[KXM?#.VDR1ME\46*-D=1@RUL>%_VE?AWXXNUM
M]%\>^"]8N&SB.RUNVN'..O".3W'YU\;Q?\&Y/P16,!O$_P 46;')_M*Q'/\
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M>6[V]Q"=KHXZ>GU!'((X(.15?1-+R!7M/PN;3O'NFV_AWQ!^[EC&S3+\?ZR
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M.@I=?M+>/M2X\RS\,K:J>^);J)C_ .B17['"JI;$U'J%%%%:&84444 %%%%
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MVEW&KI<0Z-"7#RZ9 ZI' 2%<Q[HE4,P4@,[''.*^\%_X. ?B B@+^SQJ"@<
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M $__ *4&OSH\*V,>J>)]-M9EW0W%U%%( <95G //T-?HO_P<G_\ )>/AO_V
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MM)59->G+!?FF?F_&4D\<DND5^;?ZA1103@5^P'R8C?=K\$/^"JWQ^U#]M_\
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M)J6AV;1^ /&CR7FD%%'EZ?-G,UG[!"0R<?<=1DE&-8U(]4;4Y=#[;_X(4?\
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MFZC<6%AK,VB7=^]W$CLB7,;Y6##@!Q\KJ P&6ZG]%.M&*]"2N8Q=C\'?B/\
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M'CG!KI=M &*N,;$2E?H0WMA!J5G-;W$,5Q;W"&.6*1 R2*1@JP/!!'!!ZU\
M_MF?\$!_ OQGO+O7/AG?1_#W79BTCZ<8C+H]PYY^5!\]OD_W-R 8 C%?H)13
ME%/<(R:V/P/UW_@G+^U-^PU\08?$'AGP[XD:]LY'CMM8\'2G4!,JD$[HXLRB
M-N/EFB4-T(."![=\(?\ @X7^)GPOB72OB=X!T_Q)<6Q$3W4+/HUZ<<,9$*/&
MS=\*D8[8%?L%MYJ&^TZWU2TDM[J"&XMY!AXY4#HX]P>#4>S:V97M+[H_.^V_
MX.1/A:]JK3>!?'\<V!N1%M'4'OAC,#^E<;X__P"#D9;UY+7P+\)[R\FD!$-Q
MJNIXVMVS!#&Q89["4?KD?HC)^S/\-YKP7#_#_P $M<*01*=#M2X(Z<[,UUNC
MZ%8^'M.CL]/L[6QM(1A(;>)8HT'LJ@ 4<LNX<T>Q^'GQU\?_ +9G_!0ZVBM=
M0\'>/(_"^HE6ATS3-#GTO1YAV+228$JY&<RR. >F*S/!O_!!S]HSQ1=+'>^'
MM \.JW634-<MY%7Z_9VE/Y"OW?V"E Q1[/N'M'T/G/\ X)??L:ZO^PU^R\G@
M[7[K1[W7+G5KG5+Z;3)9)+9VDV(FUI$1B1%%&#E1R#UZUXS^VC^W1^U!X!^-
M>O\ A3X7? V[U30].>.*U\03:1>:A'?!HT8R1F,I$,,Q7!+8VG/.0/O+K1MY
MJN72R)YM;L_"?XM_L'?ME?MH^,'\4>,?!_B#6M1V!(O[2U&PT]+6,DD1Q023
M1K&N<DJJCDY/)R>?T;_@E/\ M6? [Q+IOB;2?A_K&FZMI-PMS9W6FZO87$\$
MBD$,%BG8_@1@C(.1FOWXQ01FI]FBO:,_+KP#_P %#_VWO!T%M9>(/@'>>*#&
M%1KD^&KVWN)CC[S/"WE#/7(C Z_A^H%C+)/90R31>1,Z*TD>X-Y;$<KD<'!X
MR*EVT548V)E*X5\N?\%#_P!JSXU?LYZIX=M?A/\ ">X^(<6K6\[WEVEE=7B6
M,B,@1&2 @C(8G+$9QQT-?4=&.:;U$G8_%O\ :H\3_MN?MV^&QX=\0?#7Q'HW
MAMI5EFTG3-%DTZVNG0AD,K3.TCA3@A6?9E0<;E!'C]A_P19_::U*U6:/X8S*
MCYP)==TR)ASCE6N01^(K^@3;1TJ/9KJ7[1K8_G[?_@DI^U'\*]2L]8M/AYKE
MC?V<HFM;K2M9LY;FWD4C#J;>=G1@2"",'OV-?3WPD_;A_;N^$.GPZ?KGPDUW
MQU;P$*9M3\+7)NBN. );8HIQ_>96/)R2:_6;&:,4>SMLP]I?='Y]_P##SO\
M::_Z-*\4?]_;K_Y'HK]!,457*^XN9=@HHHJB VT=*** "BBB@ HHHH *,444
M &WFBBB@ HHHH ***#TH ,XK/M_%6F7>O3:5#J%E+J=O&)I;1)E::)"<;F3.
M0,D<D=Z^;?V_M>\4^!!9W5CXSOK73]9D,,>DVZ"W:)4C7>WFH0[J6/(;IO Z
M5O?\$]?A@WASX97?B2ZC;[=XDGS&SCYA!&2 <GGYG+GW 4UGS^]RFGL_=YCZ
M$HHHK0S#- .:1N17QY\'?%WQAN?VFK>WU1O$#0->$:E;W"/]AAM\G<R@_(H
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MRNKG/*-G8GU[Q#I_A?3)+S5+ZSTVSC(#SW4RPQ(2<#+,0!DG%1^'/%.E^,;
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M9_ZZ#WJO:/FL+V:Y;W/KRBBLGQOXWTOX=^&;K6-8NX[.PLUW22/W]% ZEB>
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:0@,",CUJWLQ2T4 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
